Carcaba V, Carton JA, Vicente P, Maradona JA, SanRoman F, Llorente R, Garcia Z; International Conference on AIDS.
Int Conf AIDS. 1989 Jun 4-9; 5: 332 (abstract no. T.B.P.274).
Hospital Universitario de Oviedo. Spain
OBJECTIVE: To establish the incidence, permanence and pathogenic role of PAI in HTP treated with Zidovudine, and in non-thrombocytopenic HIV-infected patients. METHODS: PAI was determined by platelet suspension immunofluorescence test to 23 HIV-infected patients with normal platelet count and 8 HTP (less than 100 x 10 platelets/L). HTP group received treatment with Zidovudine (200 mg/q 4h) during 16.6 +/- 14 weeks and PAI was again determined after thrombocytopenia remission. RESULTS: Follow-up of HTP showed initial and final platelet counts of 49000 +/- 26240 (range 79000-12000/muL) and 196667 +/- 104051 (range 321000-14000), p=0.004. There were no untoward haematological side effects. All HTP and 12 of 23 patients with normal platelets count showed PAI prior to therapy, and this situation stayed unchanged after remission with Zidovudine. One patient developed thrombocytopenia of 6000/muL while under Zidovudine. Comparison between groups were: TABULAR DATA, SEE ABSTRACT VOLUME. CONCLUSION: Zidovudine therapy appears highly effective to control HTP. The presence of PAI in that group is sensible but nonspecific. PAI may be present in every stage of HIV-infection and did not correlate with the degree of immunodeficiency or with any specific group at risk, neither did they disappear with the remission of thrombocytopenia obtained with Zidovudine. Consequently, PAI pathogenic role remains unclear.
Publication Types:
Keywords:
- AIDS Vaccines
- Acquired Immunodeficiency Syndrome
- Anti-HIV Agents
- Blood Platelets
- HIV
- HIV Infections
- HIV Seropositivity
- Humans
- Immunoglobulins
- Incidence
- Plasminogen Activator Inhibitor 1
- Plasminogen Activator Inhibitor 2
- Plasminogen Inactivators
- Platelet Count
- Thrombocytopenia
- Zidovudine
Other ID:
UI: 102177527
From Meeting Abstracts